Analysis of 4616 clinical trial initial submissions received by the Medicines and Healthcare products Regulatory Agency between February 2019 and October 2023

Documenti analoghi

• Evaluation of the Medicines and Healthcare products Regulatory Agency's introduction of a risk‐proportionate approach for clinical trials: An analysis of 4617 applications assessed between September 2023 and August 2024
  di: Andrea Manfrin, et al.
  Pubblicazione: (2025)
• Implementation of mass pharmacogenetic testing : Dihydropyrimidine dehydrogenase testing prior to fluoropyrimidine treatment for patients
  di: Nisha Shaunak, et al.
  Pubblicazione: (2025)
• Performance of the accelerated assessment of the European Medicines Agency
  di: Vittorio Del Grosso, et al.
  Pubblicazione: (2025)
• Evidence generation throughout paediatric medicines life cycle: findings from collaborative work between European Medicines Agency (EMA) and EUnetHTA on use of extrapolation
  di: Dominik Karres, et al.
  Pubblicazione: (2024)
• Transgender people in clinical trials of drugs and biologics: An analysis of ClinicalTrials.gov from 2007 to 2023
  di: Zachary Schonrock, et al.
  Pubblicazione: (2024)